Publicou 12 edições por ano
ISSN Imprimir: 1521-9437
ISSN On-line: 1940-4344
Indexed in
In Vitro and In Vivo Antidiabetic Evaluation of Selected Culinary-Medicinal Mushrooms (Agaricomycetes)
RESUMO
Management of type 2 diabetes by delaying or preventing glucose absorption using natural products is gaining significant attention. Edible mushrooms are well documented for their nutritional and medicinal properties. This investigation was designed to evaluate the antidiabetic activity of aqueous extracts of selected culinary-medicinal mushrooms, namely, Pleurotus ostreatus, Calocybe indica, and Volvariella volvacea, using in vitro models (α-amylase inhibition assay, glucose uptake by yeast cells, and glucose adsorption capacity). The most active extract was subsequently examined in vivo using the oral starch tolerance test in mice. All prepared extracts showed dose-dependent inhibition of α-amylase and an increase in glucose transport across yeast cells. C. indica extract was the most active α-amylase inhibitor (half-maximal inhibitory concentration, 18.07 ± 0.75 mg/mL) and exhibited maximum glucose uptake by yeast cells (77.53 ± 0.97% at 35 mg/mL). All extracts demonstrated weak glucose adsorption ability. The positive in vitro tests for C. indica paved the way for in vivo studies. C. indica extract (200 and 400 mg/kg) significantly (P < 0.05) reduced postprandial blood glucose peaks in mice challenged with starch. The extract (400 mg/kg) and acarbose normalized blood glucose levels at 180 minutes, when they were statistically similar to values in normal mice. Thus, it may be concluded that the antidiabetic effect of C. indica is mediated by inhibition of starch metabolism (α-amylase inhibition), increased glucose uptake by peripheral cells (promotion of glucose uptake by yeast cells), and mild entrapment (adsorption) of glucose. Hence, C. indica can be developed as antidiabetic drug after detailed pharmacological studies.
-
Ganesan , Xu , Anti-Diabetic Effects and Mechanisms of Dietary Polysaccharides, Molecules, 24, 14, 2019. Crossref
-
Kaul Sanjana, Choudhary Malvi, Gupta Suruchi, Agrawal Dinesh Chandra, Dhar Manoj K., Diversity and Medicinal Value of Mushrooms from the Himalayan Region, India, in Medicinal Mushrooms, 2019. Crossref
-
Badalyan Susanna M., Barkhudaryan Anush, Rapior Sylvie, Recent Progress in Research on the Pharmacological Potential of Mushrooms and Prospects for Their Clinical Application, in Medicinal Mushrooms, 2019. Crossref
-
Azeem Uzma, Hakeem Khalid Rehman, Ali M., Bioactive Constituents and Pharmacological Activities, in Fungi for Human Health, 2020. Crossref
-
Atri Narender Singh, Mridu , Progress of Mushroom Research in India, in Progress in Mycology, 2021. Crossref
-
Madiwalar Vaishnavi Shankar, Dwivedi Prarambh S. R., Patil Ashwini, Gaonkar Soham M. N., Kumbhar Vrunda J., Khanal Pukar, Patil B. M., Ficus benghalensis promotes the glucose uptake- Evidence with in silico and in vitro, Journal of Diabetes & Metabolic Disorders, 21, 1, 2022. Crossref
-
Li Hui, Liu Bingxiao, Bess Kezia, Wang Zhengxuan, Liang Mingcai, Zhang Yan, Wu Qiong, Yang Lin, Impact of Low-Temperature Storage on the Microstructure, Digestibility, and Absorption Capacity of Cooked Rice, Foods, 11, 11, 2022. Crossref
-
Ajith Thekkuttuparambil A., Janardhanan Kainoor K., Antidiabetic Properties of Medicinal Mushrooms with Special Reference to Phellinus Species: A Review, The Natural Products Journal, 11, 2, 2021. Crossref
-
Elbermawi Ahmed, Darwish Mohamed Samir, Zaki Ahmed A., Abou-Zeid Noha A., Taher Mohamed A., Khojah Ebtihal, Bokhari Somaiah A., Soliman Amal F., In Vitro Antidiabetic, Antioxidant, and Prebiotic Activities of the Chemical Compounds Isolated from Guizotia abyssinica, Antioxidants, 11, 12, 2022. Crossref